CORPORATE PROFILE
Founded: 1981
IPO: February 1, 2002
NASDAQ: ZGEN
www.zymogenetics.com
Overview
ZymoGenetics creates novel protein drugs
with the potential to significantly help
patients fight their diseases. The Company
is developing a diverse pipeline of
proprietary product candidates that are
moving into and through clinical development.
These span a wide array of clinical opportunities,
including bleeding, autoimmune and viral diseases
and cancer. ZymoGenetics intends to commercialize
these product candidates through internal
development, collaborations with partners
and out-licensing of patents from its extensive
patent portfolio.
Highlights
- Track record of success. ZymoGenetics
has been actively involved in the discovery
and development of therapeutic protein-based
products for more than 25 years. During that time,
the Company has contributed to the discovery
or development of six recombinant protein
products currently marketed by other
companies. These products have aggregate
annual sales of more than $3 billion.
- Focused on therapeutic protein-based products. ZymoGenetics is engaged
in the discovery and development of
novel therapeutic protein-based products
for the prevention or treatment of human
disease. The Company has an extensive
pipeline in various stages of research
and development that target a broad
range of diseases and conditions.
- Strong foundation in protein discovery. At the core of ZymoGenetics'
discovery engine is the Company's long-standing
expertise in biology, protein chemistry
and molecular and cellular biology.
Recognizing the power of genomics to
revolutionize the discovery process,
ZymoGenetics combined its core technologies
with bioinformatics to establish a portfolio
of novel protein product candidates.
- Leading intellectual property
position in potential therapeutic proteins.
ZymoGenetics' early focus on therapeutic
proteins has enabled the Company to
build an extensive patent portfolio,
with more than 300 issued or allowed
United States patents. In addition,
ZymoGenetics has more than 650 issued
or allowed foreign patents.
- Deep pipeline of product candidates.
ZymoGenetics has a growing pipeline
of potential products that will be developed
independently or in collaboration with
partners.
RECOTHROM™ Thrombin, topical (Recombinant) has been approved by the FDA. In clinical development
are three proteins discovered from bioinformatics
research efforts. Additionally, ZymoGenetics
has established a pipeline of novel
protein product candidates that are
in various stages of research and development
and are potential treatments for a variety
of diseases and conditions.
- Breadth of clinical opportunities.
ZymoGenetics' portfolio of therapeutic
protein candidates encompasses a broad
range of clinical indications. The depth
of ZymoGenetics' portfolio allows the
Company to develop selected products
in-house, while forming strategic partnerships
to advance the progress of its other
product candidates.
Product Pipeline
ZymoGenetics is developing product candidates
that target several markets, including bleeding,
cancer and autoimmune diseases.
- RECOTHROM™ Thrombin, topical (Recombinant)
- Approved by U.S. Food and Drug Administration on January 17, 2008
- is a recombinant form of thrombin,
an enzyme that stimulates the formation
of blood clots, in development
as a topical hemostat to control bleeding
- under a co-promotion agreement with Bayer HealthCare
- Atacicept
- is a soluble receptor with potential
applications for the treatment of
autoimmune diseases, including systemic
lupus erythematosus and rheumatoid
arthritis, as well as for B-cell
malignancies
- is under joint development between
ZymoGenetics and Merck Serono
- Interleukin 21 (IL-21)
- is a cytokine that regulates
natural killer cells and cytotoxic
T-cells with potential applications
for the treatment of cancer
- is licensed to Novo Nordisk A/S
for commercialization outside of
North America while ZymoGenetics
retains commercialization rights
within North America
- PEG-interferon lambda (IL-29)
- is a cytokine being developed
as a
potential treatment for patients
infected with hepatitis C
|
Back to top
